|
Cellectar prototype outperforms free paclitaxel
August 2016
SHARING OPTIONS:
MADISON, Wis.—Biotechnology company Cellectar Biosciences
Inc. has reported that the results of a preliminary tumor-targeting study revealed that CLR 1602, its prototype paclitaxel chemotherapeutic conjugate,
may be up to 30 times more tumor-selective than free paclitaxel. The in-vivo study—which was designed to evaluate the pharmacokinetics,
absorption and distribution after a single intravenous administration of CLR 1602 vs. free paclitaxel mice—showed that tumor uptake of CLR 1602’s
paclitaxel payload increased by more than 30-fold over free paclitaxel. In addition, CLR 1602’s payload demonstrated an extended plasma half-life as
well, with prolonged retention even at 96 hours, compared to free paclitaxel, which was cleared from plasma within 24 hours. Cellectar presented a poster on
these results at the recent 35th National Medicinal Chemistry Symposium in Chicago in late June.
Back |
Home |
FAQs |
Search |
Submit News Release |
Site Map |
About Us |
Advertising |
Resources |
Contact Us |
Terms & Conditions |
Privacy Policy
|